钙通道阻滞剂的使用与帕金森病风险。
Calcium channel blocker use and risk of Parkinson's disease.
机构信息
Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
出版信息
Mov Disord. 2010 Sep 15;25(12):1818-22. doi: 10.1002/mds.23191.
Abstract
We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.
摘要
我们在两项大型前瞻性队列研究中调查了钙通道阻滞剂（CCB）的使用是否与帕金森病（PD）风险降低相关：护士健康研究（NHS）和健康专业人员随访研究（HPFS）。使用 Cox 比例风险模型来估计相对风险（RR）和 95％置信区间（CI），以评估使用 CCB 与 PD 风险之间的关联，并在调整潜在混杂因素后进行评估。我们在随访期间确定了 514 例 PD 新发病例。在基线时使用 CCB（RR = 1.18，95％CI：0.73-1.92）、使用 CCB 的频率或使用 CCB 的持续时间与 PD 风险之间没有关联（所有 P > 0.2）。这些发现不支持 CCB 在提供神经保护以预防 PD 发展方面的作用。
相似文献
1
Calcium channel blocker use and risk of Parkinson's disease.钙通道阻滞剂的使用与帕金森病风险。
Mov Disord. 2010 Sep 15;25(12):1818-22. doi: 10.1002/mds.23191.
2
Use of calcium channel blockers and myocardial infarction in hypertensive patients with rheumatoid arthritis - A nationwide cohort study.钙通道阻滞剂在高血压合并类风湿关节炎患者中的应用与心肌梗死——一项全国性队列研究。
J Formos Med Assoc. 2020 Jan;119(1 Pt 2):350-358. doi: 10.1016/j.jfma.2019.06.005. Epub 2019 Jun 27.
3
Calcium channel blockers and beta-blockers in relation to Parkinson's disease.钙通道阻滞剂和β受体阻滞剂与帕金森病的关系。
Parkinsonism Relat Disord. 2007 Apr;13(3):165-9. doi: 10.1016/j.parkreldis.2006.08.011. Epub 2006 Oct 19.
4
Beta-blockers for hypertension.用于治疗高血压的β受体阻滞剂。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.
5
Calcium channel blockers for people with chronic kidney disease requiring dialysis.用于需要透析的慢性肾病患者的钙通道阻滞剂。
Cochrane Database Syst Rev. 2020 Oct 1;10(10):CD011064. doi: 10.1002/14651858.CD011064.pub2.
6
Genetic determinants of hair color and Parkinson's disease risk.头发颜色的遗传决定因素与帕金森病风险
Ann Neurol. 2009 Jan;65(1):76-82. doi: 10.1002/ana.21535.
7
Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study.抗高血压药物与帕金森病风险：一项全国性队列研究。
PLoS One. 2014 Jun 9;9(6):e98961. doi: 10.1371/journal.pone.0098961. eCollection 2014.
8
Influence of calcium channel blockers in patients with gastrointestinal disease in Japanese community pharmacies.日本社区药店中钙通道阻滞剂对胃肠道疾病患者的影响。
J Clin Pharm Ther. 2012 Feb;37(1):74-7. doi: 10.1111/j.1365-2710.2011.01253.x. Epub 2011 Mar 13.
9
Calcium Channel blockers are associated with reduced risk of Parkinson's disease in patients with hypertension: A population-based retrospective cohort study.钙通道阻滞剂与高血压患者帕金森病风险降低相关：一项基于人群的回顾性队列研究。
J Neurol Sci. 2021 May 15;424:117412. doi: 10.1016/j.jns.2021.117412. Epub 2021 Mar 24.
10
Beta-blockers for hypertension.用于治疗高血压的β受体阻滞剂。
Cochrane Database Syst Rev. 2017 Jan 20;1(1):CD002003. doi: 10.1002/14651858.CD002003.pub5.
引用本文的文献
1
Exploring Risk and Protective Factors in Parkinson's Disease.探索帕金森病的风险因素和保护因素。
Cells. 2025 May 14;14(10):710. doi: 10.3390/cells14100710.
2
Calcium channel blockers and Parkinson's disease: a systematic review and meta-analysis.钙通道阻滞剂与帕金森病：一项系统评价和荟萃分析
Ther Adv Neurol Disord. 2024 May 19;17:17562864241252713. doi: 10.1177/17562864241252713. eCollection 2024.
3
PINK1 and Parkin regulate IPR-mediated ER calcium release.PINK1 和 Parkin 调节 IPR 介导的内质网钙释放。
Nat Commun. 2023 Aug 25;14(1):5202. doi: 10.1038/s41467-023-40929-z.
4
Shared Molecular Targets in Parkinson's Disease and Arterial Hypertension: A Systematic Review.帕金森病与动脉高血压的共同分子靶点：一项系统综述
Biomedicines. 2022 Mar 11;10(3):653. doi: 10.3390/biomedicines10030653.
5
Identifying Therapeutic Agents for Amelioration of Mitochondrial Clearance Disorder in Neurons of Familial Parkinson Disease.鉴定可改善家族性帕金森病神经元中线粒体清除障碍的治疗药物。
Stem Cell Reports. 2020 Jun 9;14(6):1060-1075. doi: 10.1016/j.stemcr.2020.04.011. Epub 2020 May 28.
6
The Changing Landscape of Parkinson Epidemiologic Research.帕金森流行病学研究格局的变化。
J Parkinsons Dis. 2018;8(1):1-12. doi: 10.3233/JPD-171238.
7
A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).一项关于伊拉地平治疗早期帕金森病的III期试验（STEADY-PD III）的新颖设计。
Ann Clin Transl Neurol. 2017 May 9;4(6):360-368. doi: 10.1002/acn3.412. eCollection 2017 Jun.
8
Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status.钙通道拮抗剂作为帕金森病的疾病修饰疗法：治疗原理与现状
CNS Drugs. 2016 Dec;30(12):1127-1135. doi: 10.1007/s40263-016-0393-9.
9
Risk of Parkinson's Disease in the Users of Antihypertensive Agents: An Evidence from the Meta-Analysis of Observational Studies.抗高血压药物使用者患帕金森病的风险：来自观察性研究荟萃分析的证据
J Neurodegener Dis. 2016;2016:5780809. doi: 10.1155/2016/5780809. Epub 2016 Jul 19.
10
Reduced Risk of Parkinson's Disease in Users of Calcium Channel Blockers: A Meta-Analysis.钙通道阻滞剂使用者患帕金森病风险降低：一项荟萃分析
Int J Chronic Dis. 2015;2015:697404. doi: 10.1155/2015/697404. Epub 2015 Feb 3.
本文引用的文献
1
Use of antihypertensives and the risk of Parkinson disease.抗高血压药物的使用与帕金森病风险
Neurology. 2009 Feb 10;72(6):578-9. doi: 10.1212/01.wnl.0000344171.22760.24.
2
Use of antihypertensives and the risk of Parkinson disease.抗高血压药物的使用与帕金森病风险
Neurology. 2008 Apr 15;70(16 Pt 2):1438-44. doi: 10.1212/01.wnl.0000303818.38960.44. Epub 2008 Feb 6.
3
Calcium, ageing, and neuronal vulnerability in Parkinson's disease.钙、衰老与帕金森病中的神经元易损性
Lancet Neurol. 2007 Oct;6(10):933-8. doi: 10.1016/S1474-4422(07)70246-6.
4
'Rejuvenation' protects neurons in mouse models of Parkinson's disease.“恢复活力”可保护帕金森病小鼠模型中的神经元。
Nature. 2007 Jun 28;447(7148):1081-6. doi: 10.1038/nature05865. Epub 2007 Jun 10.
5
Calcium and neurodegeneration.钙与神经退行性变
Aging Cell. 2007 Jun;6(3):337-50. doi: 10.1111/j.1474-9726.2007.00275.x. Epub 2007 Feb 28.
6
Calcium channel blockers and beta-blockers in relation to Parkinson's disease.钙通道阻滞剂和β受体阻滞剂与帕金森病的关系。
Parkinsonism Relat Disord. 2007 Apr;13(3):165-9. doi: 10.1016/j.parkreldis.2006.08.011. Epub 2006 Oct 19.
7
Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's disease.帕金森病患者全血、血清、脑脊液和尿液中的微量元素和常量元素。
J Neural Transm (Vienna). 2004 Aug;111(8):1031-40. doi: 10.1007/s00702-004-0124-0. Epub 2004 Mar 19.
8
Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.男性和女性咖啡因摄入量与帕金森病风险的前瞻性研究。
Ann Neurol. 2001 Jul;50(1):56-63. doi: 10.1002/ana.1052.
9
Neuronal vulnerability in Parkinson's disease.帕金森病中的神经元易损性。
J Neural Transm Suppl. 1997;50:79-88. doi: 10.1007/978-3-7091-6842-4_9.
10
Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease.帕金森病患者线粒体转化的细胞中钙稳态的改变。
J Neurochem. 1997 Mar;68(3):1221-33. doi: 10.1046/j.1471-4159.1997.68031221.x.
Zotero 插件